Katie's Story

May 25, 2023

As a self-proclaimed “raging extrovert,” Katie Smith-Parent has always been open and outspoken about her life. From showing off her home, a labour of love that she and her husband have renovated and made their own, to sharing the passion for inclusion and diversity in the energy sector that earned her a spot among Calgary’s Top 40 Under 40 in 2022, Katie is an open book.


Her determination to advocate for and empower those around her has had a lasting impact in Calgary, the city she was born and raised in — but she never imagined that having the confidence to speak up would one day impact her future and save her own life.


In her early 30s, Katie noticed a lump on her breast. At a walk-in appointment, she was initially told by a doctor not to worry and that the lump would go away on its own. She had no family history of breast cancer and no other symptoms, but Katie had a feeling it was something more. She trusted her instincts and set out to find a new doctor who scheduled her for a mammogram right away. 

“I got an overnight degree in breast cancer. You would be eaten up by the system if you didn’t advocate for yourself.”

Like many younger women, Katie has dense breast tissue, which can make cancer more difficult to locate by imaging. The result of her mammogram was inconclusive, so she was sent for an ultrasound and then underwent a biopsy. This time, the results were clear. At 32 years old, Katie was diagnosed with stage two hormone-positive breast cancer. 

 

Upon diagnosis, Katie began campaigning for her own health for six months as she entered the fight of her life. “I got an overnight degree in breast cancer,” she says. “You would be eaten up by the system if you didn’t advocate for yourself.”

 

Katie is one of many young women diagnosed with breast cancer despite having no family history of the disease and no genetic markers. 

 

Most breast cancers occur in women 50 and older. While it’s less common for young women to develop breast cancer, it does happen. In fact, in North America, 18 percent of breast cancer diagnoses are women under 50.

 

And since younger women tend not to have breast cancer on their radar, their cancers tend to be detected at later stages, resulting in poorer outcomes. That’s cause for concern, says Katie.

 

“My girlfriends, we’re all in our thirties, and we had no idea how to do a breast exam. Even (at yearly) physical exams, no one does a breast exam. That’s just not a thing anymore,” says Katie. 

 

Because of her age when diagnosed with breast cancer, Katie faced a lot of unknowns when planning for her future. Before undergoing a lumpectomy, chemotherapy and radiation, she and her partner made the choice to undergo fertility preservation via in vitro fertilization (IVF) treatments. “I knew that we wanted to have children in the future,” says Katie. “We really wanted to have options.”

The good news is that Katie finished chemotherapy and radiation treatments in 2021 and is now considered “NED” or has no evidence of disease. To prevent recurrence, Katie takes hormone therapy to suppress her body’s estrogen production, complicating her ability to become pregnant in the future. 

 

Katie felt lucky to have the time and financial resources to pursue IVF following her diagnosis. It’s an opportunity that she recognizes isn’t available to every woman in her situation. That’s why Katie is using her platform in the community to amplify her own story, advocating for government-funded fertility preservation for cancer patients (oncofertility) and speaking out about the importance of early detection opportunities for younger women.

 

Katie is incredibly passionate when it comes to the importance of early detection. And as someone who advocated hard to know her own breast cancer diagnosis, this passion isn’t surprising. “It’s literally life or death,” she says.

Syantra press release graphic dated November 14, 2023
14 Nov, 2023
Syantra announces additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease.
01 Nov, 2023
CALGARY, AB. - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DX™ Breast Cancer , announced that Rob Lozuk has been appointed as Chief Executive Officer, effective November 1, 2023. “Rob brings over 23 years of experience successfully scaling and transacting commercially disruptive technologies across the healthcare landscape,” said Kristina Rinker, PhD, Chief Scientific Officer and Co-founder of Syantra. “We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection. Rob will bring substantial value to our organization as we expand into the United States with commercial introduction of the Syantra DX™ Breast Cancer test, a blood test that identifies individuals who may have breast cancer, including early-stage disease.” “The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable. Entirely too many early-stage cancers are still being missed, at a time when the opportunity for intervention and survival is the greatest. Truly disruptive healthcare technologies are generational – and that’s exactly what Syantra’s liquid biopsy platform will become” states CEO of Syantra, Rob Lozuk, and adds, “I’m thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena. Our AI-powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body’s immune response that allows cancer to develop. We will rapidly expand the clinical data of the Syantra DX™ Breast Cancer blood test over the remainder of 2023 in preparation for broad global commercialization in 2024.” Within the precision biotech space, Syantra’s liquid biopsy platform has already demonstrated impressive performance statistics as exemplified in the Analytical and Clinical Performance from the Early Analysis of the International Identify Breast Cancer (IDBC) Study, presented by Professor Nigel Bundred, Surgical Oncologist with the Manchester University NHS Foundation Trust, Wythenshawe Hospital, at the 13th European Breast Cancer Conference in Barcelona, Spain, in November of 2022. About Rob Lozuk Prior to joining Syantra, Rob was the Chief Business Officer at Cardea Bio, which culminated in a sale to Paragraf in 2023. Rob was also the President of Specific Diagnostics, which was sold to bioMérieux in 2022. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, a pioneer in revolutionizing the prenatal space, which was successfully transacted to Lab Corp (LH). Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific’s Advanced Staining Business and served as Director of Sales, Marketing and Business Development. About Syantra, Inc. Syantra is a precision biotechnology company changing the way cancer is detected and treated with revolutionary high-performance blood-based tests providing a new way to help detect cancer. Syantra’s scalable, patent-protected platform is based on changes in the immune system and other systemic factors that occur when a cancer tumor is present. These changes can be measured through mRNA biomarkers that are contained in a small amount (2.5ml) of blood. When biomarker expression is combined with patient characteristics, there is a high correlation to the presence or absence of disease. The Syantra platform includes a custom real-time PCR process with proprietary software that includes machine learning-based algorithms. Syantra’s blood testing platform provides a cost-effective way to help identify individuals who may have cancer and should be further evaluated. About the Syantra DX™ Breast Cancer test Syantra is changing the way cancer is detected and treated. Its flagship product, Syantra DX™ Breast Cancer , is a minimally invasive and high-performance blood test for the detection of breast cancer signals at the earliest stages, when breast cancer is easier to treat. The Syantra DX™ Breast Cancer test will be available to women in Canada and the United States in early 2024.
Cara Campbell, breast cancer survivor, poses for a photo with her grandson, Rhett.
22 Aug, 2023
At age 29, Cara woke up with a small lump on her chest. Cara made sure to visit her doctor right away for a thorough breast exam and mammogram. Two weeks later, after an ultrasound and a biopsy, Cara was diagnosed with breast cancer.
Syantra Press Release graphic dated April 18, 2023
18 Apr, 2023
Syantra announced today that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Olesya Kharenko stands in front of Syantra lab in lab coat.
08 Feb, 2023
The typical career journey for a scientist is fairly linear. But a lens focused on only one speciality can make it challenging to leverage the many ways these disciplines can crossover. Imagine the possibilities of a single scientist who brings expertise from more than three disciplines to research. Syantra found that in Olesya Kharenko, PhD.
Syantra press release dated January 18, 2023 announcing promotion of Carol Roesler to VP
16 Jan, 2023
Syantra Inc. announced today the promotion of Carol Roesler to Vice President, effective January 2023. Carol will maintain her current responsibilities in her new role, in addition to supporting Canadian business development for the Syantra DX™ Breast Cancer test.
Syantra DX Breast Cancer requisition with blood test tube
08 Nov, 2022
Syantra will present findings from the IDBC Study at the 13th European Breast Cancer Conference, held in Barcelona, Spain from 16 -18 November 2022.
Syantra press release dated October 27, 2022 announcing appointment of Dr. Massimo Cristofanilli
27 Oct, 2022
Syantra appoints Dr. Massimo Cristofanilli, a world-renowned leader in the field of breast cancer, to its Scientific Advisory Board (SAB) effective Sept 1, 2022. Dr. Cristofanilli is a Professor of Medicine, Chief of Breast Medical Oncology and Associate Director of Precision Medicine at Weill-Cornell Medicine.
Jesslyn Davies, a 33-year-old woman battling breast cancer, smiling in her Calgary home
18 Oct, 2022
In November 2020, Jesslyn Davies, a 33-year-old registered nurse and mother of two young boys, noticed a small cyst on her breast. Soon after, she was diagnosed with Triple Negative Stage 2B breast cancer.
Matalyn Schall poses with Syantra team wearing white lab coats at Syantra lab.
06 Oct, 2022
Since winning Miss Junior Teen Calgary pageant in April 2022, Matalyn Schall has been raising awareness of the importance of early breast cancer detection. That's when she found Syantra, a precision health care company that can detect breast cancer in the blood even at the earliest stages.
More Posts
Share by: